Pharming Group NL0010391025

Takhzyro

1. [verwijderd] 12 april 2019 10:12

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   nog maar eens dit bericht naar voren/boven halen wat m.i de reden is van de "aanval" van Shire/takeda op Pharming,
   
   Cost-effectiveness doubts could hit Shire’s Takhzyro launch
   ..
   Vertex’s cystic fibrosis therapies can step aside – there are some new contenders for the dubious honour of being the least cost-effective drug. An analysis by the US Institute for Clinical and Economic Review (Icer) has concluded that Shire’s hereditary angioedema drugs Cinryze and Takhzyro are among the priciest it has ever evaluated.
   
   This could be particularly damaging for the newcomer, Takhzyro. EvaluatePharma sellside consensus forecasts 2024 sales of $1.5bn, making the drug more valuable than the rest of Shire’s pipeline put together – so anything that might hold back its launch would be bad news for the company.
   
   Takhzyro got the FDA’s blessing in August; in the run-up to approval Bernstein analysts noted that the Icer report and resistance from payers would probably be among the biggest hurdles standing in the way of a successful launch (Shire dodges pricing questions as lanadelumab’s big day nears, August 9, 2018).
   
   Pricing backlash
   
   It looks like the backlash has begun. The Icer report released yesterday concluded that, with a net price tag of $16,500 per dose, prophylactic therapy with Takhzyro would cost a staggering $1m per quality-adjusted life year (QALY) gained.
   
   Shire’s older HAE drug Cinryze outdid even this, costing $5.9m per QALY gained, according to Icer. Although Takhzyro is more expensive than Cinryze, the former was found to lead to a greater reduction in the number of HAE attacks, in turn reducing acute treatment costs. HAE is a genetic condition characterised by episodes where various parts of the body swell.
   
   The report also evaluated CSL’s product, Haegarda, and had planned to review Pharming’s Ruconest, but the latter was removed after a recent FDA rejection for prophylactic use.
   
   en ik denk dat dit nu volop gaande is cq speelt bij Shire en daarom aaanval op pharming hun "grootste" concurrent vwb Her. ang.
   
   www.evaluate.com/vantage/articles/new...
2. [verwijderd] 12 april 2019 10:38

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   geloof nu maar dat Shire/Tak , pharming volop aan het volgen is en daarom is het ook m.i van het grootste belang dat Pharming zich zo weinig als mogelijk boven de "oppervlakte" begeeft want wat dacht je als zodadelijk Pharming met de pleisters gaat komen als nieuwe toedieningsvorm want die is dan toch ook toepasbaar voor andere medicijnen pompe/fabry...toch?